Targeted therapy in mesenchymal diseases - preclinical drug testing in vivo

Speaker: Dr Agnieszka Wożniak (Leuven Cancer Institute, Belgium)

Talk: Targeted therapy in mesenchymal diseases - preclinical drug testing in vivo

Time: 26 May 2017, 9 am

Venue: Intercollegiate Faculty of Biotechnology, Abrahama 58

Dr Agnieszka Wozniak obtained her master degrees at the Faculty of Pharmacy, MUG (1996) and at the Intercollegiate Faculty of Biotechnology UG-MUG (1998). In 2001 she received her PhD in medical biology (specialization: medical genetics) at the Faculty of Medicine MUG. After a postdoctoral fellowship at the Department of Human Genetics, KU Leuven, she became a Research Manager at the Laboratory of Experimental Oncology, Department of Oncology, KU Leuven. She is a molecular biologist with a special interest in biology and treatment of mesenchymal tumors. For several years she was involved in routine molecular diagnostics of solid tumors including soft tissue sarcoma. She has expertise in the application of various molecular techniques for the sarcomas’ classification and the determination of prognostic and predictive biomarkers. Currently her research interests include pre-clinical studies of novel targeted therapies in sarcomas, especially using patient-derived xenograft models of soft tissue sarcoma. Moreover she is heavily involved in translational research, aimed at identifying molecular markers predicting patients’ response to the targeted treatment, where she applies “liquid biopsy” approach.